Tevia Pollard

Tevia K. Pollard

Partner
Tevia K. Pollard
Boston
+1 617 570 1084

Tevia Pollard is a partner in Goodwin’s Business Law department and a member of its Technology and Life Sciences groups and Public M&A / Corporate Governance practice. Tevia primarily focuses on mergers and acquisitions, securities offerings, financings, corporate governance, and securities law compliance.

Tevia has extensive experience representing buyers and sellers in merger and acquisition transactions involving both public and private companies, particularly in the technology and life sciences industries. In this practice, she has a special focus on public company mergers and acquisitions, and other complex transactions involving public companies.

Experience

Tevia’s notable representations include:

  • Citrix Systems in its go-private transaction valued at $16.5 billion pursuant to which affiliates of Vista Equity Partners, and Evergreen Coast Capital Corporation, an affiliate of Elliott Investment Management L.P., acquired Citrix
  • Slack in its $27.7 billion sale to Salesforce
  • Virtusa in its $2 billion sale to Baring Private Equity Asia
  • Edgio in its acquisition of Edgecast from Yahoo
  • Roman DBDR Tech Acquisition Corp. in its $1.2 billion business combination with CompoSecure
  • Mobeewave in its $115 million sale to Apple
  • Control4 in its $680 million sale to SnapAV, a portfolio company of Hellman & Friedman
  • Twilio in its $3 billion acquisition of SendGrid

  • EQRx in its sale to Revolution Medicines in an all-stock transaction intended to add more than $1 billion in net cash to Revolution Medicines’ balance sheet
  • Orchard Therapeutics in its pending sale to Kyowa Kirin for $387 million and contingent value rights (CVRs)
  • TCR2 in its cross-border all-stock combination with Adaptimmune
  • Concert Pharmaceuticals in its sale to Sun Pharma for $576 million in upfront cash plus CVRs
  • Forma Therapeutics in its $1.1 billion sale to Novo Nordisk
  • Checkmate in its $250 million sale to Regeneron
  • MyoKardia in its $13.1 billion sale to Bristol Myers Squibb
  • Xeris in in its cross-border acquisition of Strongbridge Biopharma for stock and CVRs valued at $267 million
  • Chiasma in its cross-border sale to Amryt Pharma
  • Centerbridge Partners in its $1.4 billion acquisition of Civitas Solutions
  • VBL Therapeutics in its “reverse” merger with Notable Labs
  • Aerpio in its “reverse” merger with Aadi Bioscience, concurrent $155 million PIPE financing, and related CVRs
  • Unum in its simultaneous sign and close “reverse” merger with Kiq Bio (operating as Cogent Biosciences), concurrent $104 million PIPE financing, and related CVRs
  • Zafgen in its “reverse” merger with Chondrial Therapeutics (operating as Larimar Therapeutics)

  • Wayfair in its $1.5 billion convertible note offering
  • Wayfair in its $535 million convertible note offering
  • Leading investment banks in Knowbe4’s initial public offering on the NYSE

Professional Activities

Tevia serves on the Board of Trustees of Spaulding Rehabilitation, Inc. She is also a member of the Boston Bar Association and the Massachusetts Black Lawyers Association.

Credentials

Education

JD2015

Boston College Law School

AB2012

Princeton University

Admissions

Bars

  • Massachusetts
  • New York

Recognition & Awards

Tevia was recognized as one of six Law360 Rising Stars in Mergers & Acquisitions in 2023.

Tevia was also recognized in The Best Lawyers in America, Ones to Watch for Mergers and Corporate Governance and Compliance Law, Mergers and Acquisitions Law, and Technology Law (2023, 2024), and was named to The National Black Lawyers Top 40 Under 40 list (2021).

Upon graduating law school, Tevia was the recipient of the Richard G. Huber Award for her scholarship and leadership in extra and co-curricular activities.

While attending law school, Tevia served as the Administrative Editor for the Uniform Commercial Code Reporter-Digest.